

Laurence Camoin-Jau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9422530/publications.pdf>

Version: 2024-02-01

71
papers

3,134
citations

304743

22
h-index

155660

55
g-index

81
all docs

81
docs citations

81
times ranked

3825
citing authors

#	ARTICLE	IF	CITATIONS
1	Case series of massive direct oral anticoagulant ingestion "Treatment and pharmacokinetics data. European Journal of Clinical Investigation, 2022, , e13746.	3.4	5
2	Mitral valve repair is better than mitral valve replacement in native mitral valve endocarditis: Results from a prospective matched cohort. Archives of Cardiovascular Diseases, 2022, 115, 160-168.	1.6	2
3	The Antibacterial Effect of Platelets on Escherichia coli Strains. Biomedicines, 2022, 10, 1533.	3.2	4
4	Platelets and Escherichia coli: A Complex Interaction. Biomedicines, 2022, 10, 1636.	3.2	6
5	Ultrastructure of a late-stage bacterial endocarditis valve vegetation. Journal of Thrombosis and Thrombolysis, 2021, 51, 821-826.	2.1	4
6	Statins potentiate the antibacterial effect of platelets on <i>Staphylococcus aureus</i> . Platelets, 2021, 32, 671-676.	2.3	8
7	Different pattern of the second outbreak of COVID-19 in Marseille, France. International Journal of Infectious Diseases, 2021, 102, 17-19.	3.3	12
8	Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. Reviews in Cardiovascular Medicine, 2021, 22, 1063.	1.4	21
9	Clinical validation of immunoassay HemosIL [®] AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia. Journal of Thrombosis and Thrombolysis, 2021, 52, 601-609.	2.1	5
10	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. Journal of Microbiology, Immunology and Infection, 2021, 54, 37-45.	3.1	5
11	¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of native valve infective endocarditis: A prospective study. Archives of Cardiovascular Diseases, 2021, 114, 211-220.	1.6	12
12	Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy. Journal of Clinical Medicine, 2021, 10, 1565.	2.4	3
13	Infective endocarditis with neurological complications: Delaying cardiac surgery is associated with worse outcome. Archives of Cardiovascular Diseases, 2021, 114, 527-536.	1.6	10
14	Drug Response Diversity: A Hidden Bacterium?. Journal of Personalized Medicine, 2021, 11, 345.	2.5	2
15	Single or triple positivity for antiphospholipid antibodies in "carriers" or symptomatic patients: Untangling the knot. Journal of Thrombosis and Haemostasis, 2021, 19, 3018-3030.	3.8	9
16	Effect of antiplatelet agents on platelet antistaphylococcal capacity: An in vitro study. International Journal of Antimicrobial Agents, 2020, 55, 105890.	2.5	9
17	The distinct effects of aspirin on platelet aggregation induced by infectious bacteria. Platelets, 2020, 31, 1028-1038.	2.3	8
18	Heparin-Induced Thrombocytopenia in Severe COVID-19. Circulation, 2020, 142, 1875-1877.	1.6	62

#	ARTICLE	IF	CITATIONS
19	A Novel Approach for Detecting Unique Variations among Infectious Bacterial Species in Endocarditic Cardiac Valve Vegetation. <i>Cells</i> , 2020, 9, 1899.	4.1	9
20	Spondylodiscitis complicating infective endocarditis. <i>Heart</i> , 2020, 106, 1914-1918.	2.9	13
21	Antiplatelet Agents Have a Distinct Efficacy on Platelet Aggregation Induced by Infectious Bacteria. <i>Frontiers in Pharmacology</i> , 2020, 11, 863.	3.5	17
22	Comparison Between ESC and Duke Criteria for the Diagnosis of Prosthetic Valve Infective Endocarditis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2605-2615.	5.3	35
23	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , 2020, 36, 101791.	3.0	209
24	Natural history of COVID-19 and therapeutic options. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1159-1184.	3.0	101
25	Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting. <i>Frontiers in Medicine</i> , 2020, 7, 599626.	2.6	11
26	Aspirin Effect on Staphylococcus aureus Platelet Interactions During Infectious Endocarditis. <i>Frontiers in Medicine</i> , 2019, 6, 217.	2.6	19
27	The hidden side of oral thrombin inhibitors. <i>International Journal of Cardiology</i> , 2019, 274, 186-187.	1.7	0
28	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. <i>Platelets</i> , 2019, 30, 105-111.	2.3	3
29	Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 465-473.	3.8	7
30	Rapid identification of microorganisms from platelet concentrates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry after short-term incubation on liquid medium. <i>Transfusion</i> , 2018, 58, 766-773.	1.6	2
31	Comparing two blood culture systems for the detection of bacterial contamination in platelet concentrates. <i>Transfusion</i> , 2018, 58, 2604-2610.	1.6	5
32	Intracranial haemorrhage in infective endocarditis. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 712-721.	1.6	33
33	Platelet Reactivity. <i>Journal of the American College of Cardiology</i> , 2017, 69, 114.	2.8	2
34	Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2017, 103, e9-e10.	1.3	2
35	Thrombosis and antiphospholipid antibody syndrome during acute Q fever. <i>Medicine (United States)</i> , 2017, 96, e7578.	1.0	19
36	Coronary events complicating infective endocarditis. <i>Heart</i> , 2017, 103, 1906-1910.	2.9	28

#	ARTICLE	IF	CITATIONS
37	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2560-2570.	2.9	36
38	In vitro detection of bacterial contamination in platelet concentrates by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: a preliminary study. <i>Journal of Medical Microbiology</i> , 2017, 66, 1523-1530.	1.8	3
39	Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2016, 220, 496-500.	1.7	11
40	Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2015, 114, 702-707.	3.4	18
41	Enhanced Prevalence of Plasmatic Soluble MHC Class I Chain-Related Molecule in Vascular Pregnancy Diseases. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	4
42	Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 872-877.	2.8	247
43	Biological efficacy and clinical safety of a second 600 mg loading dose of clopidogrel in elderly patients with high on-treatment platelet reactivity: A pilot study. <i>International Journal of Cardiology</i> , 2013, 165, 200-201.	1.7	1
44	A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. <i>International Journal of Cardiology</i> , 2013, 168, 4244-4248.	1.7	14
45	Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?. <i>Current Pharmaceutical Design</i> , 2012, 18, 5392-5401.	1.9	2
46	Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Hospital Practice (1995)</i> , 2012, 40, 104-117.	1.0	1
47	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. <i>Thrombosis Research</i> , 2012, 130, 70-74.	1.7	12
48	Factor VIII:C levels in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 116, 258-259.	2.3	1
49	TCT-737 Relationship between post treatment platelet reactivity and ischemic and bleeding events at one year follow-up in acute coronary syndrome patients receiving prasugrel. <i>Journal of the American College of Cardiology</i> , 2012, 60, B215.	2.8	0
50	Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2012, 108, 101-106.	3.4	22
51	High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2011, 58, 467-473.	2.8	196
52	Platelets and endothelium: Two key players in percutaneous coronary intervention. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 601-603.	1.6	2
53	High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. <i>Critical Care</i> , 2011, 15, R31.	5.8	80
54	Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2011, 108, 1710-1713.	1.6	34

#	ARTICLE	IF	CITATIONS
55	Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. <i>Thrombosis and Haemostasis</i> , 2010, 104, 410-411.	3.4	14
56	Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. <i>Thrombosis and Haemostasis</i> , 2010, 104, 456-463.	3.4	153
57	Level of Adenosine Diphosphate Receptor P2Y12 Blockade During Percutaneous Coronary Intervention Predicts the Extent of Endothelial Injury, Assessed by Circulating Endothelial Cell Measurement. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1024-1031.	2.8	27
58	Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19*2 Loss of Function Polymorphism. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1630-1636.	2.8	110
59	Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 Δ loss of function polymorphism. <i>International Journal of Cardiology</i> , 2010, 145, 165-166.	1.7	11
60	Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. <i>Thrombosis Research</i> , 2010, 125, e167-e170.	1.7	20
61	Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2010, 126, e147-e149.	1.7	37
62	Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. <i>Platelets</i> , 2010, 21, 503-507.	2.3	27
63	Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1525-1532.	1.5	1
64	TRAIL/Apo2L Mediates the Release of Procoagulant Endothelial Microparticles Induced by Thrombin In Vitro. <i>Circulation Research</i> , 2009, 104, 943-951.	4.5	72
65	Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis. <i>American Journal of Cardiology</i> , 2009, 103, 5-10.	1.6	271
66	Relation of Body Mass Index to High On-Treatment Platelet Reactivity and of Failed Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2009, 104, 1511-1515.	1.6	78
67	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2008, 101, 1088-1093.	1.6	194
68	Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1404-1411.	2.8	531
69	A threshold of platelet reactivity for ischaemic events?. <i>European Heart Journal</i> , 2008, 29, 2185-2186.	2.2	0
70	Soluble MHC Class I chain-related molecule serum levels are predictive markers of implantation failure and successful term pregnancies following IVF. <i>Human Reproduction</i> , 2007, 22, 2261-2266.	0.9	19
71	Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. <i>Blood</i> , 2007, 110, 2432-2439.	1.4	181